IBDEI1YL ; ; 17-FEB-2016
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;JUN 29, 2015
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,99) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,33248,2)
 ;;=^5009023
 ;;^UTILITY(U,$J,358.3,33249,0)
 ;;=L03.031^^131^1669^111
 ;;^UTILITY(U,$J,358.3,33249,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,33249,1,3,0)
 ;;=3^Cellulitis of Right Toe
 ;;^UTILITY(U,$J,358.3,33249,1,4,0)
 ;;=4^L03.031
 ;;^UTILITY(U,$J,358.3,33249,2)
 ;;=^5009025
 ;;^UTILITY(U,$J,358.3,33250,0)
 ;;=L03.032^^131^1669^104
 ;;^UTILITY(U,$J,358.3,33250,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,33250,1,3,0)
 ;;=3^Cellulitis of Left Toe
 ;;^UTILITY(U,$J,358.3,33250,1,4,0)
 ;;=4^L03.032
 ;;^UTILITY(U,$J,358.3,33250,2)
 ;;=^5009026
 ;;^UTILITY(U,$J,358.3,33251,0)
 ;;=L03.041^^131^1669^26
 ;;^UTILITY(U,$J,358.3,33251,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,33251,1,3,0)
 ;;=3^Acute Lymphangitis of Right Toe
 ;;^UTILITY(U,$J,358.3,33251,1,4,0)
 ;;=4^L03.041
 ;;^UTILITY(U,$J,358.3,33251,2)
 ;;=^5009028
 ;;^UTILITY(U,$J,358.3,33252,0)
 ;;=L03.042^^131^1669^20
 ;;^UTILITY(U,$J,358.3,33252,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,33252,1,3,0)
 ;;=3^Acute Lymphangitis of Left Toe
 ;;^UTILITY(U,$J,358.3,33252,1,4,0)
 ;;=4^L03.042
 ;;^UTILITY(U,$J,358.3,33252,2)
 ;;=^5009029
 ;;^UTILITY(U,$J,358.3,33253,0)
 ;;=M34.0^^131^1669^249
 ;;^UTILITY(U,$J,358.3,33253,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,33253,1,3,0)
 ;;=3^Progressive Systemic Sclerosis
 ;;^UTILITY(U,$J,358.3,33253,1,4,0)
 ;;=4^M34.0
 ;;^UTILITY(U,$J,358.3,33253,2)
 ;;=^5011778
 ;;^UTILITY(U,$J,358.3,33254,0)
 ;;=M34.1^^131^1669^91
 ;;^UTILITY(U,$J,358.3,33254,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,33254,1,3,0)
 ;;=3^CR(E)ST Syndrome
 ;;^UTILITY(U,$J,358.3,33254,1,4,0)
 ;;=4^M34.1
 ;;^UTILITY(U,$J,358.3,33254,2)
 ;;=^5011779
 ;;^UTILITY(U,$J,358.3,33255,0)
 ;;=M34.2^^131^1669^273
 ;;^UTILITY(U,$J,358.3,33255,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,33255,1,3,0)
 ;;=3^Systemic Sclerosis Induced by Drug/Chemical
 ;;^UTILITY(U,$J,358.3,33255,1,4,0)
 ;;=4^M34.2
 ;;^UTILITY(U,$J,358.3,33255,2)
 ;;=^5011780
 ;;^UTILITY(U,$J,358.3,33256,0)
 ;;=M34.81^^131^1669^275
 ;;^UTILITY(U,$J,358.3,33256,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,33256,1,3,0)
 ;;=3^Systemic Sclerosis w/ Lung Involvement
 ;;^UTILITY(U,$J,358.3,33256,1,4,0)
 ;;=4^M34.81
 ;;^UTILITY(U,$J,358.3,33256,2)
 ;;=^5011781
 ;;^UTILITY(U,$J,358.3,33257,0)
 ;;=M34.82^^131^1669^276
 ;;^UTILITY(U,$J,358.3,33257,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,33257,1,3,0)
 ;;=3^Systemic Sclerosis w/ Myopathy
 ;;^UTILITY(U,$J,358.3,33257,1,4,0)
 ;;=4^M34.82
 ;;^UTILITY(U,$J,358.3,33257,2)
 ;;=^5011782
 ;;^UTILITY(U,$J,358.3,33258,0)
 ;;=M34.83^^131^1669^277
 ;;^UTILITY(U,$J,358.3,33258,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,33258,1,3,0)
 ;;=3^Systemic Sclerosis w/ Polyneuropathy
 ;;^UTILITY(U,$J,358.3,33258,1,4,0)
 ;;=4^M34.83
 ;;^UTILITY(U,$J,358.3,33258,2)
 ;;=^5011783
 ;;^UTILITY(U,$J,358.3,33259,0)
 ;;=M34.89^^131^1669^274
 ;;^UTILITY(U,$J,358.3,33259,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,33259,1,3,0)
 ;;=3^Systemic Sclerosis NEC
 ;;^UTILITY(U,$J,358.3,33259,1,4,0)
 ;;=4^M34.89
 ;;^UTILITY(U,$J,358.3,33259,2)
 ;;=^5011784
 ;;^UTILITY(U,$J,358.3,33260,0)
 ;;=M34.9^^131^1669^278
 ;;^UTILITY(U,$J,358.3,33260,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,33260,1,3,0)
 ;;=3^Systemic Sclerosis,Unspec
 ;;^UTILITY(U,$J,358.3,33260,1,4,0)
 ;;=4^M34.9
 ;;^UTILITY(U,$J,358.3,33260,2)
 ;;=^5011785
 ;;^UTILITY(U,$J,358.3,33261,0)
 ;;=R21.^^131^1669^257
 ;;^UTILITY(U,$J,358.3,33261,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,33261,1,3,0)
 ;;=3^Rash/Nonspecific Skin Eruption
 ;;^UTILITY(U,$J,358.3,33261,1,4,0)
 ;;=4^R21.
